FDA Panel Rules Against NeurogesX Patch for HIV-Related Neuropathy
February 15, 2012
A Food and Drug Administration panel of outside experts has ruled against using a product derived from chili peppers to treat neuropathic pain in people with HIV. The committee voted 12-0 that clinical data do not show substantial evidence that NeurogesX Inc.'s Qutenza is effective against pain in the extremities suffered by many HIV patients. The experts also voted 11-0, with one abstention, that the capsaicin patch's risk-benefit profile was not acceptable for use by persons with HIV.
02.09.2012; David Morgan
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)